References
- Aysegül B, Veysi GH, Muzaffer M, et al (2011). Is a single nucleotide polymorphism a risk factor for lung cancer in the matrix metalloproteinase-2 promoter? Mol Biol Rep, 38, 1469-74. https://doi.org/10.1007/s11033-010-0253-5
- Baltazar-Rodriguez LM, Anaya-Ventura A, Andrade-Soto M, et al (2008). Polymorphism in the matrix metalloproteinase-2 gene promoter is associated with cervical neoplasm risk in Mexican women. Biochem Genet, 46, 137-144. https://doi.org/10.1007/s10528-007-9136-4
- Bergers G, Brekken R, Mcmahon G, et al (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol, 2, 737-744. https://doi.org/10.1038/35036374
- Bjorklund M, Koivunen E (2005). Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta, 1755, 37-69.
- Bonomi P (2002). Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol, 29, 78-86. https://doi.org/10.1053/sonc.2002.31528
- Burton PR, Hansell AL, Fortier I, et al (2009). Size matters: just how big is BIG? Quantifying realistic sample size requirements for human genome epidemiology. Int J Epidemiol, 38, 263-73. https://doi.org/10.1093/ije/dyn147
- Chaudhary AK, Pandya S, Mehrotra R, et al (2011). Role of functional polymorphism of matrix metalloproteinase-2 (-1306 C/T and -168 G/T) and MMP-9 (-1562 C/T) promoter in oral submucous fibrosis and head and neck squamous cell carcinoma in an Indian population. Biomarkers, 16, 577-86. https://doi.org/10.3109/1354750X.2011.609602
- Cohn LD, Becker BJ (2003). How meta-analysis increases statistical power. Psychol Methods, 3, 243-53.
- Cox TR, Erler JT (2011). Remodeling and homeostasis of the extracellular matrix: Implications for fibrotic diseases and cancer. Dis Model Mech, 4, 165-78. https://doi.org/10.1242/dmm.004077
- Curran S, Murray GI (1999). Matrix metallproteinases in tumor invasion and metastasis. J Pathol, 189, 300-8. https://doi.org/10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C
- Delgado-Enciso I, Cepeda-Lopez FR, Monrroy-Guizar EA, et al (2008). Matrix metalloproteinase-2 promoter polymorphism is associated with breast cancer in a Mexican population. Gynecol Obstet Invest, 65, 68-72. https://doi.org/10.1159/000108282
- DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-188. https://doi.org/10.1016/0197-2456(86)90046-2
- Deryugina EI, Quigley JP (2006). Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev, 25, 9-34. https://doi.org/10.1007/s10555-006-7886-9
- Dos Reis ST, Pontes J Jr, Villanova FE, et al (2009). Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer. J Urol, 181, 2320-5. https://doi.org/10.1016/j.juro.2009.01.012
- Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 7109, 629-34.
- Elander N, Soderkvist P, Fransen K (2006). Matrix metalloproteinase (MMP) -1, -2, -3 and -9 promoter polymorphisms in colorectal cancer. Anticancer Res, 26, 791-5.
- Guo X, Wang J, Zhang L, et al (2012). Quantitative assessment of the effects of MMP-2 polymorphisms on lung carcinoma risk. Asian Pac J Cancer Prev, 13, 2853-6 https://doi.org/10.7314/APJCP.2012.13.6.2853
- Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-674. https://doi.org/10.1016/j.cell.2011.02.013
- Hettiaratchi A, Hawkins NJ, McKenzie G, et al (2007). The collagenase-1 (MMP-1) gene promoter polymorphism - 1607/2G is associated with favourable prognosis in patients with colorectal cancer. Br J Cancer, 96, 783-792. https://doi.org/10.1038/sj.bjc.6603630
- Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. BMJ, 7414, 557-60. https://doi.org/10.1136/bmj.327.7414.557
- Hu C, Wang J, Xu Y, et al (2013). Current evidence on the relationship between five polymorphisms in the matrix metalloproteinases (MMP) gene and lung cancer risk: a meta-analysis. Gene, 517, 65-71. https://doi.org/10.1016/j.gene.2012.12.085
- Itoh T, Tanioka M, Yoshida H, et al (1998). Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res, 58, 1048-51.
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Kader AK, Shao L, Dinney CP, et al (2006). Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res, 66, 11644-8. https://doi.org/10.1158/0008-5472.CAN-06-1212
- Kang SH, Brown DA, Kitajima I, et al (1996). Binding and functional effects of transcriptional factor Sp1 on the murine interleukin-6 promotor. J Biol Chem, 271, 7330-5. https://doi.org/10.1074/jbc.271.13.7330
- Kumar R, Malik N, Tungaria A, Kawal P (2011). Matrix metalloproteinase-2 gene polymorphism is not associated with increased glioblastoma multiforme susceptibility: an Indian institutional experience. Neurol India, 59, 236-240. https://doi.org/10.4103/0028-3886.79131
- Lebeau A, Muller-Aufdemkamp C, Allmacher C, et al (2004). Cellular protein and mRNA expression patterns of matrix metalloproteinases- 2, -3 and -9 in human breast cancer: correlation with tumour growth. J Mol Histol, 35, 443-455.
- Lei H, Hemminki K, Altieri A, et al (2007). Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat, 103, 61-69. https://doi.org/10.1007/s10549-006-9345-2
- Li X, Qu L, Zhong Y, et al (2013). Association between promoters polymorphisms of matrix metalloproteinases and risk of digestive cancers: a meta-analysis. J Cancer Res Clin Oncol, 139, 1433-47. https://doi.org/10.1007/s00432-013-1446-9
- Li Y, Sun DL, Duan YN, et al (2010). Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China. Mol Biol Rep, 37, 197-205. https://doi.org/10.1007/s11033-009-9593-4
- Lichtenstein P, Holm NV, Verkasalo PK, et al (2000). Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med, 343, 78-85. https://doi.org/10.1056/NEJM200007133430201
- Lin SC, Lo SS, Liu CJ, et al (2004). Functional genotype in matrix metalloproteinases-2 promoter is a risk factor for oral carcinogenesis. J Oral Pathol Med, 33, 405-9. https://doi.org/10.1111/j.1600-0714.2004.00231.x
- Liu D, Guo H, Li Y, et al (2012). Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis. PLoS One, 7, 31251. https://doi.org/10.1371/journal.pone.0031251
- Mandal RK, Yadav SS, Panda AK (2013). Meta-analysis on the association of nucleotide excision repair gene XPD A751C variant and cancer susceptibility among Indian population. Mol Biol Rep. (Epub ahead of print)
- Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 4, 719-48.
- Martin MD, Matrisian LM (2007). The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev, 26, 717-24. https://doi.org/10.1007/s10555-007-9089-4
- Miao X, Yu C, Tan W, et al (2003). A functional polymorphism in the matrix metalloproteinase-2 gene promoter (-1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res, 63, 3987-90.
- Nabeshima K, Inoue T, Shimao Y, Sameshima T (2002). Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int, 52, 255-64. https://doi.org/10.1046/j.1440-1827.2002.01343.x
- O-Charoenrat P, Khantapura P (2006). The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncol, 42, 257-67. https://doi.org/10.1016/j.oraloncology.2005.07.008
- Ohtani H, Maeda N, Murawaki Y (2009). Functional polymorphisms in the promoter regions of matrix metalloproteinase-2, -3, -7, -9 and TNF-alpha genes, and the risk of colorectal neoplasms in Japanese. Yonago Acta Medica, 52, 47-56.
- Pan MR, Hung WC (2002). Nonsteroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 via suppression of the ERK/ Sp1-mediated transcription. Proc Natl Acad Sci USA, 277, 32775-380.
- Pharoah PD, Dunning AM, Ponder BA, Easton DF (2004). Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer, 4, 850-60. https://doi.org/10.1038/nrc1476
- Price SJ, Greaves DR, Watkins H (2001). Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem, 276, 7549-58. https://doi.org/10.1074/jbc.M010242200
- Price SJ, Greaves DR, Watkins H (2001). Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem, 276, 7549-58. https://doi.org/10.1074/jbc.M010242200
- Roehe AV, Frazzon AP, Agnes G, et al (2007). Detection of polymorphisms in the promoters of matrix metalloproteinases 2 and 9 genes in breast cancer in South Brazil: preliminary results. Breast Cancer Res Treat, 102, 123-4. https://doi.org/10.1007/s10549-006-9273-1
- Rollin J, Regina S, Vourc'h P, et al (2007). Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer, 56, 273-80. https://doi.org/10.1016/j.lungcan.2006.11.021
- Saeed HM, Alanazi MS, Parine NR, et al (2013). Matrix metalloproteinase-2 (-1306 c>t) promoter polymorphism and risk of colorectal cancer in the saudi population. Asian Pac J Cancer Prev, 14, 6025-30. https://doi.org/10.7314/APJCP.2013.14.10.6025
- Satpute SP, Hazarey VK, Ganvir SM (2012). Estimation of matrix metalloproteinases-2 promoter polymorphism as a risk factor for oral carcinogenesis in Indian population. Scientific reports, 1, 1-4. https://doi.org/10.9734/JSRR/2012/2008
- Shalaby MA, Nounou HA, Alanazi MS, et al (2014). Associations between single nucleotide polymorphisms of COX-2 and MMP-2 genes and colorectal cancer susceptibility in the Saudi population. Asian Pac J Cancer Prev, 15, 4989-4994. https://doi.org/10.7314/APJCP.2014.15.12.4989
- Srivastava P, Kapoor R, Mittal RD (2013). Association of single nucleotide polymorphisms in promoter of matrix metalloproteinase-2, 8 genes with bladder cancer risk in Northern India. Urol Oncol, 31, 247-54. https://doi.org/10.1016/j.urolonc.2011.01.001
- Srivastava P, Lone TA, Kapoor R, Mittal RD (2012). Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in North India. Arch Med Res, 43, 117-24. https://doi.org/10.1016/j.arcmed.2012.02.006
- Sternlicht MD, Werb Z (1999). Matrix metalloproteinase. In Kreis T and Vale R (eds) guidebook to the extracellular matrix, anchor and adhesion proteins. Oxford University Press, New York, 503-603.
- van Kempen LC, de Visser KE, Coussens LM (2006). Inflammation, proteases and cancer. Eur J Cancer, 42, 728-34. https://doi.org/10.1016/j.ejca.2006.01.004
- Vihinen P, Kahari VM (2002). Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer, 99, 157-166. https://doi.org/10.1002/ijc.10329
- Wagenaar-Miller RA, Gorden L, Matrisian LM (2004). Matrix metalloproteinases in colorectal cancer: is it worth talking about? Cancer Metastasis Rev, 23, 119-135. https://doi.org/10.1023/A:1025819214508
- Wieczorek E, Reszka E, Jablonowski Z, et al (2013). Genetic polymorphisms in matrix metalloproteinases (MMPs) and tissue inhibitors of MPs (TIMPs), and bladder cancer susceptibility. BJU Int, 112, 1207-14. https://doi.org/10.1111/bju.12230
- Woolf B (1955). On estimating the relation between blood group and disease. Ann Hum Genet, 19, 251-3. https://doi.org/10.1111/j.1469-1809.1955.tb01348.x
- Wu R, Li B (1999). A multiplicative-epistatic model for analyzing interspecific differences in outcrossing species. Biometrics, 2, 355-65.
- Xu E, Lai M, Lv B, et al (1999). A single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer. Biochem Biophys Res Commun, 324, 999-1003.
- Yang L, Li N, Wang S, et al (2014). Lack of association between the matrix metalloproteinase-2 -1306C>T polymorphism and breast cancer susceptibility: a meta-analysis. Asian Pac J Cancer Prev, 15, 4823-7 https://doi.org/10.7314/APJCP.2014.15.12.4823
- Yaykasli KO, Kayikci MA, Yamak N, et al (2014). Polymorphisms in MMP-2 and TIMP-2 in Turkish patients with prostate cancer. Turk J Med Sci, 44.
- Yu C, Pan K, Xing D, et al (2002). Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res, 62, 6430-33.
- Yu C, Zhou Y, Miao X, et al (2004). Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res, 64, 7622-8. https://doi.org/10.1158/0008-5472.CAN-04-1521
- Zhai Y, Qiu W, Dong XJ, et al (2007). Functional polymorphisms in the promoters of MMP-1, MMP-2, MMP-3, MMP-9, MMP-12 and MMP-13 are not associated with hepatocellular carcinoma risk. Gut, 56, 445-7. https://doi.org/10.1136/gut.2006.112706
- Zhou Y, Yu C, Miao X, et al (2004). Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis, 25, 399-404.
- Zhou Y, Yu C, Miao X, et al (2005). Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis, 26, 1117-21. https://doi.org/10.1093/carcin/bgi057
Cited by
- Interleukin-16 polymorphisms as new promising biomarkers for risk of gastric cancer vol.37, pp.2, 2016, https://doi.org/10.1007/s13277-015-4013-y
- The association between MMP2 −1306 C > T (rs243865) polymorphism and risk of prostate cancer vol.186, pp.1, 2017, https://doi.org/10.1007/s11845-016-1492-9